STOCK TITAN

IRulya Therapeutics: Ikarian reports 2.3% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

IRulya Therapeutics Inc. (IRLA) is named in an amended Schedule 13G reporting that Ikarian Capital, LLC and Neil Shahrestani each report the same 254,058-share beneficial-ownership position, or 2.3%, with shared voting and dispositive power over those shares. The shares are held by Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts managed by Ikarian Capital; Shahrestani may be deemed to own them indirectly through his control of Ikarian Capital. Each reporting person says the statement is not an admission of beneficial ownership. The reported percentage is based on 10,841,470 shares outstanding as of November 5, 2026.

Beneficial ownership 254,058 shares The same position is reported by Ikarian Capital, LLC and Neil Shahrestani.
Percentage of class 2.3% Based on 10,841,470 common shares outstanding as of November 5, 2026.
Shared voting power 254,058 shares Reported by each reporting person.
Shared dispositive power 254,058 shares Reported by each reporting person.
Common shares outstanding 10,841,470 shares As of November 5, 2026; used as the basis for the reported percentage of class.
beneficial ownership regulatory
"may be deemed to have beneficial ownership of the securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared voting power regulatory
"Shared Voting Power 254,058.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power regulatory
"Shared Dispositive Power 254,058.00"
investment discretion regulatory
"through the investment discretion it has over the Fund and the Managed Accounts"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many IRLA shares do Ikarian Capital and Neil Shahrestani report owning?

Ikarian Capital, LLC and Neil Shahrestani each report the same beneficial-ownership position of 254,058 shares, equal to 2.3% of the class. The shares are held by Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts managed by Ikarian Capital.

What voting and disposition authority do Ikarian Capital and Neil Shahrestani report over IRLA shares?

They report shared voting power and shared dispositive power over 254,058 shares; sole voting power and sole dispositive power are each reported as zero.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





22053A305

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: (1) The figures in Items 6, 8, and 9 represent common stock, par value $0.001 ("Common Stock") of IRulya Therapeutics Inc. (the "Issuer"), held by Ikarian Healthcare Master Fund, L.P., a Cayman Islands exempted limited partnership (the "Fund"), and certain separately managed accounts. See Item 2 for more information. (2) The figure in Item 11 is based upon 10,841,470 shares of Common Stock of the Issuer outstanding as of November 5, 2026, as disclosed in the Issuer's Form 10-Q for the quarterly period ended September 30, 2026, filed with the U.S. Securities and Exchange Commission (the "SEC") on November 13, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: (1) The figures in Items 6, 8, and 9 represent Common Stock of the Issuer, held by the Fund and certain separately managed accounts. See Item 2 for more information. (2) The figure in Item 11 is based upon 10,841,470 shares of Common Stock of the Issuer outstanding as of November 5, 2026, as disclosed in the Issuer's Form 10-Q for the quarterly period ended September 30, 2026, filed with the SEC on November 13, 2026.


SCHEDULE 13G



Ikarian Capital, LLC
Signature:/s/ Neil Shahrestani
Name/Title:Neil Shahrestani, Sole Manager
Date:11/16/2026
Neil Shahrestani
Signature:/s/ Neil Shahrestani
Name/Title:Neil Shahrestani
Date:11/16/2026
Exhibit Information

A Joint Filing Agreement is incorporated herein by reference to Exhibit 99.1 to the Schedule 13G filed on December 15, 2025 by the Reporting Persons with the SEC.

Keep reading